Aimmune Therapeutics
(Web: www.aimmune.com)

Aimmune is a biopharmaceutical company developing proprietary products and advancing a therapeutic approach for the treatment of peanut and other food allergies.

The company’s mission is to improve the lives of people with food allergies, which they are doing through the development of desensitisation treatments. Their aim is to address food allergies by providing a treatment option in addition to the current recommendations of avoiding exposure to food allergens and the need to carry adrenaline for administration in case of accidental exposure.

The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from exposure to food allergens by desensitising patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product, AR101, is being developed as a treatment to reduce the frequency and severity of adverse events following exposure to peanut.